When first approved Xarelto was intended to be taken to prevent deep vein thrombosis, pulmonary embolism, and blood clots after hip or knee replacement.

Source: An Overview Of FDA Warnings Amid Xarelto Lawsuit Filings

It would appear that the focus on the Xarelto multidistrict litigation is starting to come together. The first trial dates for the Philadelphia mass tort are

Source: First Xarelto Trial Dates Set as Mass Tort Filings Increase | LawInfo Blog

The $70 million verdict a Philadelphia jury levied against Janssen Pharmaceuticals on July 1 may not survive challenges that it is excessive, but the award was a definitive win for the plaintiffs in the Risperdal mass tort litigation, attorneys who work in the pharmaceutical arena said.

A Philadelphia jury July 1 returned the award against Janssen and in favor of a boy who claimed the antipsychotic drug, Risperdal, led to excess growth of breast tissue. The plaintiffs in A.Y. v. Janssen Pharmaceuticals had argued that the company knew the medication caused the condition, but failed to properly inform the medical community, emphasizing potential profits for the drug over its safety.

Attorney Jason Itkin from the Houston-based firm Arnold & Itkin tried the case for the plaintiffs, and Drinker Biddle & Reath attorney David Abernethy tried the case for Janssen.

The award, according to Duane Morris attorney Alan Klein, who often represents generic-drug companies, was a "quantum leap" in the litigation, as the previous highest verdict in the Risperdal mass tort had been a $2.5 million award.

Mass torts attorney Max Kennerly of Kennerly Loutey, who represents plaintiffs, agreed that the verdict was an "obvious" win for the plaintiffs, and said it put much of the leverage in the plaintiffs' hands. He noted the verdict was the fifth time a jury found the company negligently failed to warn about the drug, and said the latest verdict indicates the potential for the damages as well.

"It seems that as this moves forward, the liability proof and the causation proof are just getting stronger and stronger," Kennerly said. "I don't see much of an upside for the defendants."

However, attorneys noted that an appeal is coming, and several questioned whether the full amount will survive a remittitur challenge.

Although attorneys agreed it is impossible to predict how a court may rule on an issue, one attorney noted that in the case Polett v. Public Communications, the state Superior Court recently struck down as excessive a $27.6 million verdict over a knee implant.

"I'd rather be the appellee than appellant ... but I don't see how they can substantiate a verdict for those damages," Cozen O'Connor products liability attorney James Heller said.

Kennerly agreed, but added that, even if the verdict is reduced, it could still be very significant.

"The number is huge. It's difficult to see such a number surviving intact through an appeal," Kennerly said. "That said, the jury has very wide latitude to determine the extent of damages and to assess them appropriately."

Klein, who represents both plaintiffs and defendants in products liability cases, said that, although the plaintiffs are sympathetic, the size of the verdict showed the jury was angry.

The plaintiffs in the Risperdal mass tort all took the medication to help control mental health issues, including symptoms related to autism, Tourette syndrome and, in the latest case, violent oppositional behavior. Klein observed the injuries are not life threatening or a major impairment of life activities. He surmised that the size of the verdict was intended to signal to the drugmaker the jurors' disapproval of the company's conduct.

"It leaves me to suspect the jury was very unhappy at the defendant," Klein said. "Something that came out at the trial set the jury off significantly."

VIEW FULL ARTICLE

Source: The Legal Intelligencer

Despite ongoing federal and state litigation, defendants Bayer HealthCare AG and Janssen Pharmaceuticals have broadcast a TV commercial for more than a year, where celebrities tout the dangerous dr…

Source: Defendants Use Celebrities to Promote Xarelto Despite Ongoing Litigation

As the number of IVC filter lawsuits continues to climb, a two-part investigation by NBC Nightly News in September of last year continues to be the preeminent touchstone for the consumer on what the inferior vena cava filter is, its role in preventing blood clots and its risks due to filter migration.

Source: IVC Filter Lawsuits Keep Piling Up Over Allegedly Flawed Device

Nearly 5,000 Testosterone lawsuits have been filed against drug manufacturers including AbbVie Inc., Auxilium Pharmaceuticals, and Endo Pharmaceuticals Inc. as part of multidistrict litigation dock…

Source: Testosterone Litigation Rising Amid Claims of Heart Attacks and Strokes | The National Trial Lawyers

The Zoloft birth defect MDL ends with Pfizer’s victory as U.S. District Judge Cynthia Rufe granted the company's motion for summary judgment yesterday.

Source: Zoloft Birth Defect MDL Ends with Pfizer’s Victory - Legal Reader

"One in six seniors in the U.S. regularly uses potentially dangerous combinations of prescription and over-the-counter medications and dietary supplements, according to new research. The study, published today in JAMA Internal Medicine, showed a two-fold increase over a five-year period."

Source: Many seniors using dangerous drug combinations - CBS News

The first symptoms mimicked the flu. Becki Conway had a sore throat, a dry cough and irritated sinuses.

Source: Prescription for harm: Dangerous drug mix leaves woman fighting for life - Chicago Tribune

NEW BRUNSWICK, NJ—Johnson & Johnson (J&J) has made a serious move to settle thousands of lawsuits filed by women who assert they suffered injuries from vaginal mesh inserts made by its

Source: J&J to Pay $120 Million to Settle Thousands of Vaginal Mesh Lawsuits | New Brunswick Today